Ductal Carcinoma In Situ Treatment in United Arab Emirates
- Top Accredited Hospitals
- Global Medical Standards
- Cutting-Edge Technology
- Proven Treatment Options
- High Success Rate
- Trusted by Millions
What is Ductal Carcinoma In Situ?
Ductal carcinoma in situ is an extremely early form of breast cancer. When it occurs, the cancer cells are contained within a breast milk duct, and the breast tissue is still free of cancerous cells. A common term for this type of breast cancer is DCIS. This type of breast cancer is sometimes referred to as stage 0, noninvasive, or preinvasive.
DCIS is usually found on a mammogram that is done to screen for breast cancer or to investigate a bulge in the breast. There is a minimal chance that DCIS will become invasive and threaten life. However, it must be evaluated, and treatment options must be considered.
DCIS is often treated with surgery. Other treatments may include hormone therapy or radiation therapy in addition to surgery.
What is the Importance of Timely Treatment?
Ductal Cell Carcinoma in Situ (DCIS) must be treated early to lower the chance of recurrence and spread to other body areas, as well as to stop it from developing into invasive breast cancer. Early detection reduces the psychological and physical effects of more invasive surgeries, increases survival rates, and permits breast-conserving therapy. Patients who receive immediate treatment for DCIS have a better prognosis and a higher quality of life, and their chances of the disease developing into something invasive or life-threatening are significantly decreased.
What are the Common Symptoms of Ductal Carcinoma In situ?
Usually, there are no symptoms associated with ductal carcinoma in situ. DCIS is another name for this early stage of breast cancer.
DCIS can occasionally result in symptoms like:
- A lump in the breast.
- Bloody discharge from the nipples.
Mammography is typically where DCIS is detected. In breast tissue, it manifests as microscopic calcium particles. These are calcifications, which are deposits of calcium.
Causes and Risk Factors of Ductal Carcinoma In Situ
Causes
- A non-malignant breast cancer that starts in the milk ducts is referred to as ductal carcinoma in situ (DCIS). While their exact cause is not known, risk factors are age (typically greater than 50), radiation, family history or genetic defects (e.g., BRCA1/2), hormonal imbalances, and personal history of benign breast disease.
- The risk can also be increased by lifestyle factors such as obesity, alcohol consumption, and lack of exercise, as well as previous reproductive history. Early detection screening is key to the management of DCIS.
Risk Factors
- Age
- Hormonal Factors
- History & Genetics
- Personal History of Breast Conditions
- Radiation Exposure
- Obesity
Connect with our advisor for a PRIORITY response
Latest Research and Technologies in the Treatment of Ductal Carcinoma In Situ in the United Arab Emirates
Innovative technology and research are used to treat Ductal Carcinoma In Situ (DCIS) in the United Arab Emirates. The American University of Sharjah researchers' achievement in patenting a targeted platform for chemotherapy is significant. To reduce damage to normal tissue and reduce side effects, this platform employs liposomal encapsulation of chemotherapeutic drugs in combination with antibodies like trastuzumab to target HER2-positive breast cancer cells specifically.
In addition, the United Arab Emirates has executed oncoplastic lumpectomy techniques that minimise the necessity of mastectomy and enhance the rates of breast conservation by enabling resection of as much as 50% of breast volume with preservation of breast aesthetics.
Treatment options for Ductal Carcinoma In Situ
Lumpectomy: The breast cancer and a portion of the surrounding normal tissue are cut out during a lumpectomy. There is no removal of the rest of the breast tissue. Wide local excision and breast-conserving surgery are alternative names for this procedure. Most patients who have a lumpectomy also undergo radiation therapy.
Mastectomy: The removal of all the breast tissue by operation is called a mastectomy. If you prefer, breast reconstruction to re-form the appearance of the breast may be performed at the same time or later on.
Cost Start From USD 9000 - USD 20000Explore Options
Hormone therapy: Endocrine therapy, also referred to as hormone therapy, involves using drugs that prevent the body from making specific hormones. It is applied in the treatment of breast cancers that are estrogen and progesterone-sensitive.
Cost Start From USD 100 - USD 1000Explore Options
Radiation Therapy: To reduce the risk of recurrence, radiation therapy is often given after surgery for ductal carcinoma in situ (DCIS). It is typically recommended following a lumpectomy, especially if the tumour is large or has high-risk features. High-energy X-rays are employed in the treatment to locate and kill any remaining cancer cells in the breast tissue. Radiation therapy significantly decreases the possibility that DCIS could recur.
- Mammography is the most common screening method for detecting breast calcifications that may indicate DCIS.
- Breast ultrasound is often used together with mammography to evaluate areas of concern further.
- MRI: Provides high-resolution images and helps to determine the extent of DCIS.
- Biopsy: The best test for diagnosing DCIS is a biopsy, in which tissue is removed from the suspicious region to determine whether cancer cells are present.
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services to support patients through Teleconsultations and online therapy sessions.
- Physical Therapy assists in the recovery of strength, improvement in mobility, and removal of any restrictions after surgery (e.g., mastectomy or lumpectomy).
- Lymphedema Management: Physical therapists can attempt to reduce arm or breast swelling in patients receiving radiation therapy or surgery.
- Depending on the severity of the condition, your healthcare professional may prescribe medicine to help control your symptoms and support the treatment plan.
Instantly Connect with our Specialists
Hospitals for Ductal Carcinoma In Situ in United Arab Emirates
Zulekha Hospital Sharjah
Sharjah, United Arab Emirates
Zulekha Hospital Sharjah located in Sharjah, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:
- Zulekha Hospital Sharjah is present over a 290,000 square feet area.
- The hospital stands today with a bed capacity of 185.
- The hospital also has a Cardiac Catheterization Laboratory and radiology as well as laboratory services.
- There is an ICU and Neonatal ICUs.
- There are facilities for Dialysis and advanced technological applications such as Minimal Invasive surgeries.
- In Zulekha Hospital Sharjah Bariatric procedures, Joint Replacement, Specialised Cancer Care, Cardio Thoracic and Vascular Procedure, Plastic and Reconstructive Procedure are performed.
- It also specialises in Pediatric Cardiology, Pulmonology and Chest Diseases, etc.
- Teleconsultation services as well as an international patient care center with related assistance for medical travelers are functioning in Zulekha Sharjah.
Burjeel Medical City
Abu Dhabi, United Arab Emirates
The Hospital owns an International Patient Services Team that is responsible to assist international patients with world-class healthcare, transportation arrangement, accommodation facilities, language interpreters, and much more.
Burjeel Medical City (about 1.2 million square facilities)provides 7-star hospitality to its patients. It has the largest facility space bed among all the private hospitals. The Hospital consists of-
- Large waiting areas and consultation rooms
- Spacious lobbies on each floor
- 338 Luxurious Patient Rooms
- 70 Ambulatory Rooms
- Intensive Care Units
- The Hospital comprises various centers, under Burjeel Cancer Institute-
- Breast Center
- Uro-oncology Center
- Surface Malignancy Center (HIPC)
- Head & Oncology Center
- Medical Oncology & Hematology Center and others
Zulekha Hospital Dubai
Dubai, United Arab Emirates
Zulekha Hospital Dubai located in Dubai, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:
- The bed capacity of Zulekha Hospital Dubai is 140.
- Diagnostic centers, pharmacies, inpatient and outpatient care are provided at Zulekha Hospital Dubai.
- This hospital provides the best of healthcare packages
- Its surgical base is really strong with the hospital having successfully initiated and completed minimally invasive surgeries, joint replacement surgeries, bariatric surgeries, cardiac, and neonatal surgeries.
- Radiology, laboratory, operating theatres, dialysis section and Cardiac Catheterization Laboratory are all present in Zulekha Hospital Dubai, UAE.
Our Services to better your experience
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Why Choose the United Arab Emirates for Duct Carcinoma In Situ Treatment?
The United Arab Emirates is an excellent destination for treating Duct Carcinoma In Situ (DCIS) due to its world-class medical infrastructure, highly trained medical professionals, and access to the latest technologies. The country offers comprehensive care tailored to each patient's requirements, such as radiation therapy, surgery, and targeted therapies. UAE is also a favoured destination for high-value care because the cost of medical care is often lower compared to other countries.
Frequently Asked Questions
Yes, mammography can often detect ductal carcinoma in situ (DCIS). DCIS usually appears as microcalcifications, microscopic calcium deposits that appear as white specks on X-rays. Microcalcifications can also occur with benign conditions, but when they occur in specific patterns, they can be a marker for DCIS. Mammograms are a key early detection method for DCIS, often before symptoms develop.
In the United Arab Emirates, a biopsy is the gold standard for diagnosing ductal carcinoma in situ (DCIS). While mammograms and other imaging tests can identify problematic spots, a biopsy is necessary to collect a tissue sample for microscopic analysis. Doctors can use this to effectively diagnose DCIS, evaluate its features, and choose the best course of treatment.
In the United Arab Emirates, ductal carcinoma in situ (DCIS) often needs surgery, although this depends on the individual case. Based on the size, location, and other features of the DCIS, the most frequent surgical options are mastectomy (breast removal) or lumpectomy (tumour removal).
Surgery is not always needed for DCIS, especially if the issue is detected early and can be treated with hormone therapy or radiation. After consultation with the medical team, the choice is made according to the patient's condition and personal preferences.
Mastectomy can be suggested for Ductal Carcinoma In Situ (DCIS) in the United Arab Emirates if the DCIS is large or widespread or if it occurs in several locations within the breast, so that breast-conserving surgery, such as lumpectomy, is not as effective. It can also be suggested if the patient is at high risk of recurrence or if prior surgery has not worked to remove the cancer.
Radiation therapy is often recommended in the United Arab Emirates’ healthcare environments for ductal carcinoma in situ (DCIS), particularly after a lumpectomy. It targets any remaining breast cancer cells, reducing the risk of recurrence. However, radiation therapy is not required for all DCIS patients. Tumour size, margins, grade, and other risk factors affect the decision.
In patients in the United Arab Emirates, ductal carcinoma in situ (DCIS) may recur after treatment; the risk is low if proper treatment is undertaken. The opposite or the same breast (local recurrence) can suffer from recurrence. Several factors, such as the grade of DCIS, the surgical margins, the application of radiation therapy, and the patient's overall condition, can influence the risk of recurrence. Imaging tests, monitoring, and follow-up treatment are essential in detecting early recurrence.
Women with Ductal Carcinoma In Situ (DCIS) have good survival rates in the United Arab Emirates, reflecting good early detection and effective treatment. General breast cancer survival rates are encouraging, with most women having favourable outcomes, although there are no accurate statistics available for DCIS alone. Due to the non-invasive nature of DCIS, an excellent long-term survival rate is highly dependent on early diagnosis via regular screening and exposure to advanced treatment.
Yes, you can get a second opinion on Ductal Cell Carcinoma treatment in the United Arab Emirates through MediGence. With MediGence, you can connect with highly experienced professionals from top UAE hospitals who can provide additional information regarding your diagnosis and treatment options. The platform facilitates easy access to professional help so you can make informed healthcare choices and receive the best care possible.
To find a certified cancer specialist, search MediGence’s website, which offers a list of top-class and internationally trained oncologists from the United Arab Emirates's best hospitals. Through MediGence, you can search the profiles of specialists, check their credentials, reviews, and experience, and book online consultations. To get the best care for your condition, the website also assists you in finding the best hospitals and provides personalised assistance for your health requirements.